Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Daiichi Sankyo Company, Limited
  6. News
  7. Summary
    4568   JP3475350009

DAIICHI SANKYO COMPANY, LIMITED

(4568)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Daiichi Sankyo Company, Limited and AstraZeneca Announces DESTINY-Gastric04 Head-to-Head Phase 3 Trial of ENHERTU® Initiated in Patients with HER2 Positive Advanced Gastric Cancer

07/08/2021 | 08:00am EST

Daiichi Sankyo Company, Limited and AstraZeneca announced that the first patient was dosed in DESTINY-Gastric04, a global phase 3 trial evaluating the safety and efficacy of ENHERTU® (trastuzumab deruxtecan) compared to ramucirumab/paclitaxel combination therapy in patients with HER2 positive metastatic and/or unresectable gastric or gastroesophageal junction (GEJ) adenocarcinoma with disease progression on or after a trastuzumab-containing regimen. Gastric cancer is associated with a poor prognosis, particularly in the advanced stages of the disease, with only 5% to 10% of patients surviving 5 years. One in five gastric cancers are considered HER2 positive, however loss of HER2 expression has been observed in 29% to 69% of patients with gastric cancer following treatment with trastuzumab, suggesting a decrease in HER2 expression can result in progression on trastuzumab and may be associated with poor outcomes. After progression on first-line HER2 targeted systemic treatment, second-line treatment options are limited, driving a need for new HER2 targeted therapies for these patients.


© S&P Capital IQ 2021
All news about DAIICHI SANKYO COMPANY, LIMITED
11/30Daiichi Sankyo Company, Limited Announces DESTINY-Breast11 Neoadjuvant Phase 3 Trial of..
CI
11/29Japanese drugmaker Daiichi Sankyo sets up subsidiary in Singapore
AQ
11/26Tepco finds melting of ice wall at Japan's Fukushima Daiichi plant
RE
11/18Daiichi Sankyo Announces Positive Topline Results from the Global Pivotal QuANTUM-First..
CI
11/05A decade on, Fukushima farmers fear nuclear-tainted water's impact on business
RE
11/03Trastuzumab Deruxtecan Type Ii Variation Application Validated by Ema for the Treatment..
CI
11/03Trastuzumab Deruxtecan Type II Variation Application Validated by EMA for the Treatment..
CI
11/01Daiichi Sankyo's Attributable Profit Gains in Fiscal Q2
MT
11/01Daiichi Sankyo Company, Limited Launches DELYTACT? Oncolytic Virus G47 in Japan
CI
10/29Daiichi Sankyo Company, Limited Revises Earnings Guidance for the Full Year 2022
CI
More news
Analyst Recommendations on DAIICHI SANKYO COMPANY, LIMITED
More recommendations
Financials
Sales 2022 1 021 B 9 029 M 9 029 M
Net income 2022 64 911 M 574 M 574 M
Net cash 2022 625 B 5 526 M 5 526 M
P/E ratio 2022 84,7x
Yield 2022 0,94%
Capitalization 5 456 B 48 251 M 48 247 M
EV / Sales 2022 4,73x
EV / Sales 2023 4,45x
Nbr of Employees 16 033
Free-Float 97,6%
Chart DAIICHI SANKYO COMPANY, LIMITED
Duration : Period :
Daiichi Sankyo Company, Limited Technical Analysis Chart | 4568 | JP3475350009 | MarketScreener
Technical analysis trends DAIICHI SANKYO COMPANY, LIMITED
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 14
Last Close Price 2 846,50 JPY
Average target price 3 789,29 JPY
Spread / Average Target 33,1%
EPS Revisions
Managers and Directors
Sunao Manabe President, CEO & Representative Director
Hiroyuki Okuzawa CFO, Director, Executive Officer & Head-Management
Ken Takeshita Global Director-Research & Development
Noritaka Uji Independent Outside Director
Tsuguya Fukui Independent Outside Director
Sector and Competitors
1st jan.Capi. (M$)
DAIICHI SANKYO COMPANY, LIMITED-19.48%48 251
JOHNSON & JOHNSON1.27%419 583
ROCHE HOLDING AG17.62%341 364
PFIZER, INC.44.09%304 610
NOVO NORDISK A/S64.51%244 010
ELI LILLY AND COMPANY47.55%222 641